RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY pelareorep + CD3 bispecific antibody true-killer comboSummit Therapeutics US$19.5 Billion market cap is bizzare since their Phaswe 3 clinical trials have not been conducted in the United States and while their drug was a PD-1 + VEGF inhibitior vs. keytruda - the Phase 3 trials were not run against keytruda + the VEGF Avastin and have not reported on overall survival. So while Summitt Therapeutics may run clinical trials in the United States, Summit must begin with gaining an IND for this Chinese owned (Akeso) I/O drug combination and then run a series of clinical trials starting with Phase 1 through to Phase 3 as determined by the US FDA and not the Chinese National Medical Products Administration- all conditional on the company to report on favorable overal survival data based on keytruda + Avastin data - and not on keytruda alone, as it has in all trials reported in China.